(redirected from T-cell lymphoma)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to lymphoma

a neoplasm of lymph tissue that is usually malignant

References in periodicals archive ?
The European Commission has extended the current conditional marketing authorization of Adcetris (brentuximab vedotin) and approved Adcetris for the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma after at least one prior systemic therapy, Osaka, Japan-based R and D-driven pharmaceutical company Takeda Pharmaceutical Company Ltd.
One of the challenges in treating T-cell lymphomas has been finding a way to eliminate the abnormal T-cells while sparing the healthy ones.
T-cell lymphoma typically occurs in adults older than 50 years, with a slight male predominance.
Mature T-cell lymphoma is a rare, aggressive type of cancer in which the standard of care chemotherapy regimen has not changed in decades, said Dirk Huebner, M.
T-Cell Lymphoma - Pipeline Insights, 2016 comprehensively includes:
A Phase II clinical study of the agent in patients with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma is currently underway in Japan.
Preparations are simultaneously in progress for a Phase III clinical study of the agent in patients with cutaneous T-cell lymphoma in the United States.
Lessin, "Cutaneous T-cell lymphoma epidemiology: patients providing the power," Archives of Dermatology, vol.
Primary small intestinal lymphoma maybe broadly categorized into three groups including immunoproliferative small intestinal disease (IPSID) lymphoma, enteropathy-associated T-cell lymphoma (EATL) and other western-type non-IPSID lymphomas.
A snapshot of the global therapeutic scenario for Cutaneous T-Cell Lymphoma.
Compared with a reference group of 45 cases with T-cell lymphoma and 228 controls not exposed to any of the medications (OR, 1.
Last month, the Food and Drug Administration approved Gloucester's Istodax as a treatment for cutaneous T-cell lymphoma for patients who were on at least one previous therapy.
a privately held specialty pharmaceutical company, has completed enrollment for a pivotal Phase 2 clinical trial for Clearazide for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages 1-2a).
Particular PTCL subtypes, such as angioimmunoblastic T-cell lymphoma (AITL) and NKTCL seem to have a strong association with EBV infection [66].
Updated Phase II results for the treatment of T-cell lymphoma during the second quarter of 2008;